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HB: heart beating 
HLA: human leucocyte antigen 
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DGF: delayed graft function transplant through the AM program 
DSA: donor specific antibody 
ENIS: Eurotransplant Network Information System 
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IL2RA: IL-2 receptor antagonist 
MMF: mycophenolate mofetil 
NHB: non-heart beating 
NIMA: noninherited maternal antigen 
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PRA: panel reactive antibody 
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Abstract 
Whereas regular allocation avoids unacceptable mismatches on the donor organ, allocation to highly 
sensitized patients within the Eurotransplant Acceptable Mismatch (AM) program is based on the 
patient’s HLA phenotype plus acceptable antigens. These are HLA antigens to which the patient never 
made antibodies, determined by extensive laboratory testing. AM patients have superior long-term 
graft survival compared to highly sensitized patients in regular allocation. Here, we questioned 
whether the AM program also results in lower rejection rates. From the PROCARE cohort, consisting 
of all Dutch kidney transplants 1995-2005, we selected deceased donor single transplants with 
minimum one HLA mismatch and determined the cumulative 6-month rejection incidence for patients 
in AM or regular allocation. Additionally, we determined the effect of minimal matching criteria of 
one HLA-B plus one HLA-DR, or two HLA-DR antigens on rejection incidence. AM patients showed 
significantly lower rejection rates than highly immunized patients in regular allocation, comparable to 
non-sensitized patients, independent of other risk factors for rejection. Contrasting to highly sensitized 
patients in regular allocation, minimal matching criteria did not affect rejection rates in AM patients. 
Allocation based on acceptable antigens leads to relatively low risk transplants for highly sensitized 
patients with rejection rates similar to non-immunized individuals. 
 
Introduction 
Sensitization towards Human Leucocyte Antigens (HLA) can occur through pregnancy, blood 
transfusion, or transplantation (1). When a patient has formed antibodies reactive >85% of HLA 
antigens present in the donor population, this patient is regarded as being highly sensitized (2). Highly 
sensitized patients accrue on the transplant waiting list due to the low number of available crossmatch 
negative donors. The Eurotransplant Acceptable Mismatch program was established almost 30 years 
ago with the aim to provide a chance for highly sensitized patients to be transplanted, and has resulted 
in more than 1500 transplants (3). The program is based on the positive identification of HLA 
antigens to which the patient has not made any antibodies by using extensive laboratory testing (4). 
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phenotype, which is used for allocation (5). Any available deceased donor organ that matches this 
extended phenotype is mandatorily shipped to the AM patient, resulting in lower waiting times for 
these highly sensitized patients (6, 7). Acceptable antigens are truly acceptable, since no HLA match 
effect is observed in patients transplanted through the AM program (5, 7). Previously, it was shown 
that the long-term graft survival of patients transplanted through the AM program is far superior to 
that of their highly sensitized counterparts transplanted through regular allocation, and was even 
comparable to non-sensitized patients (7, 8). Since the AM strategy is targeted at defining HLA 
antigens that are immunologically acceptable it is to be expected that allocation based on acceptable 
antigens would also result in a lower rejection incidence. Unfortunately, due to lack of registration of 
rejection data in the Eurotransplant Network Information System (ENIS), it has not been possible so 
far to determine the effect of the AM approach on rejection rates. The Dutch multi-center PROCARE 
study, which includes clinical follow-up of all kidney transplants performed between 1995 and 2005 
in the Netherlands, allowed for the first time to determine the effect of allocation based on acceptable 
mismatches on rejection rates. 
 
Methods 
The AM program  
Current eligibility criteria for inclusion into the AM program are a cumulative waiting time on the 
Eurotransplant Kidney Allocation System (ETKAS) waiting list of at least 2 years, and a complement-
dependent cytotoxicity (CDC) PRA of >85% in either historic or current serum samples. In the time 
period 1995-2005 acceptable antigens were defined by making use of mainly cellular assays as 
described elsewhere (5). Briefly, CDC assays were performed using patient specific cell panels of 
lymphocytes that had only one HLA mismatch with the patient, in which negative reactions would 
specify acceptable antigens. Similarly, a panel of K562 cells lines transfected with genes encoding 
single HLA class I alleles were used as targets in CDC. In the time period studied, solid phase assays 
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For allocation purposes, HLA matching on the patient’s own HLA antigens and additional acceptable 
antigens were performed on the split antigen level. Minimal match criteria on identity of either two 
HLA-DR antigens or one HLA-DR antigen with one HLA-B antigen at the split level were adhered 
to. For patients with a chance of receiving a kidney through the AM program of <0.1% (based on 
immunological grounds), minimal HLA matching was reduced to one HLA-DR match with the 
patient on the broad antigen level. Furthermore, whereas regular allocation through ETKAS is based 
on blood group identity, AM patients are transplanted based on blood group compatibility. 
 
Patients 
We performed a post hoc analysis on the PROCARE cohort, which includes all renal transplantations 
performed in the Netherlands between January 1995 and December 2005 with available clinical 
follow-up (9). All transplantations required a negative CDC crossmatch using both peak and current 
sera. A detailed description of the cohort has been published previously (10). Clinical data were 
obtained from the Dutch Organ Transplant Registry. Rejection was defined as the presence of biopsy-
proved acute rejection (without further classification), or any treatment for acute rejection when no 
biopsy was performed. Patients transplanted through regular allocation (ETKAS) were grouped 
according to the level of sensitization (0%–5% peak PRA: non-sensitized; 6%–85% peak PRA: 
intermediately sensitized; and >85% peak PRA: highly sensitized), as defined by CDC assays. 
Patients included on the AM waiting list remained on the ETKAS waiting list as well, and those 
actually transplanted through ETKAS (and thus received an organ based on the absence of 
unacceptable antigens only) are included in the >85% PRA ETKAS group. The study design is 
schematically depicted in supplemental Figure S1, and patient characteristics are depicted in table 1. 
All patients provided written informed consent for use of their clinical data. The study protocol was 
approved by the Biobank Research Ethics Committee of the UMC Utrecht (TC Bio 13-633) and 
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Detection and definition of DSAs by solid phase 
All available pre-transplant patient sera were retrospectively tested for the presence of donor specific 
antibodies (DSA) by luminex single antigen bead (SAB) assays and analyzed in context of the 
PROCARE study as described previously (10). 
 
Data handling  
Groupings of quantitative variables were based on the following strategies: transplant period was 
divided into 2 equal periods, recipient and donor age of 50 years were used for stratification based on 
previous studies (11). Donor type was defined as either heart beating (HB) or non-heart beating 
(NHB). Initial immunosuppression was categorized as prednisolone / cyclosporin ± MMF ± IL-2 
receptor antagonist (IL2RA) versus prednisolone / tacrolimus / MMF ± IL2RA based on a previous 
study on the complete PROCARE cohort (12). Graft function was categorized on direct or delayed 
function and HLA mismatches were divided into equal categories.  
 
Statistical analysis 
The Chi-squared test was used to test whether there is a trend in the proportions with transplant 
characteristics over the four categories. Statistical significance was determined by using the log-rank 
test, corrected for multiple comparisons (Bonferroni method), where applicable. Inclusion criterion 
for the multivariate analysis was a univariate P-value of <0.1. Multivariate Cox regression analysis 
was performed to determine independent effects on 6-month cumulative rejection incidence. P-values 
were 2-tailed, and those <0.05 were considered statistically significant. SPSS version 23 (IBM, 
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Results 
Allocation based on acceptable mismatches results in low rejection rates 
To determine the effect of allocation based on acceptable mismatches on the 6-month cumulative 
rejection incidence, we selected all deceased donor single renal transplants from 1996 to 2005 (in 
1996, ETKAS was initiated (13)) with at least one HLA antigen mismatch (HLA-A, -B or -DR) at the 
broad antigen level. We observed an increased rejection incidence with increased sensitization grade 
within regular allocation, with the highest incidence of rejection in the highly sensitized patients 
transplanted through ETKAS (Figure 1A). In contrast, highly sensitized patients transplanted through 
the AM program showed similar rejection rates to non-sensitized patients (P=1.000), and lower, 
although not significant, rejection rates as intermediately sensitized patients (P=0.423). When 
compared to their highly sensitized counterparts transplanted through regular allocation, AM patients 
experienced a significantly lower rejection incidence (P=0.004, Figure 1A). To determine the effect of 
the different allocation schemes on rejection rates later after transplant, we also analyzed the 
cumulative rejection incidence between 6 months and 5 years and observed no differences in this later 
period (Figure 1B).  
We next performed univariate Cox regression analysis on all highly sensitized patients (n=234) with 
variables that potentially affect the rejection incidence (Table 2). The variables sex and age of 
recipient and donor, donor type, first transplant versus repeat transplant, HLA mismatch grade, 
transplant period, presence of SAB detected DSA class I, class II or both class I and II, and initial 
immunosuppression did not significantly affect the cumulative 6-month rejection incidence. The only 
variables that affected the incidence of rejection were delayed graft function (HR: 1.94; 95% CI: 1.19 
to 3.17; P=0.008) and receiving a transplant through the AM program (HR: 0.47; 95% CI: 0.29 to 
0.76; P=0.002). The variables transplant period, initial immunosuppression, initial graft function and 
transplant through the AM program were selected for subsequent multivariate analysis to determine 
whether the effect of receiving a transplant through the AM program was independent. For initial 
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immunosuppression protocols outside the two main immunosuppression categories. To exclude an 
interaction between initial immunosuppression and transplant through the AM program we first 
analysed these variables in a separate multivariate analysis and observed only a minimal effect of 
initial immunosuppression on the variable transplant through the AM program (HR changes from 0.47 
to 0.54, Table 2). Subsequent multivariate analysis on transplant period, initial immunosuppression, 
initial graft function and transplant through the AM program showed that only delayed graft function 
(HR: 1.93; 95% CI: 1.16 to 3.19; P=0.011) and receiving a transplant through the AM program (HR: 
0.57; 95% CI: 0.34 to 0.95; P=0.029) were independently associated with 6-month cumulative 
rejection incidence (Table 2). 
 
Minimal match criteria do not result in lower rejection rates in AM patients 
It has previously been shown that AM patients transplanted with a minimal match level of two HLA-
DR antigens, or one HLA-DR and one HLA-B antigen have similar graft survival rates compared to 
AM patients without this minimal level of HLA matching, raising the possibility that the minimal 
match criteria for AM patients could be abandoned (3). Importantly, in the current cohort we were 
able to determine the effect of the minimal match criteria on rejection rates. For this analysis, we 
included also patients with zero HLA mismatches (Figure S1). We found that receiving a transplant 
without the aforementioned minimal match level, but a minimum match of one HLA-DR on the broad 
antigen level, significantly increased the 6-month cumulative rejection incidence in patients 
transplanted through ETKAS (P<0.0001, Figure 2A), whereas no effect was found in the AM cohort 
(P=0.700, Figure 2B). The data indicate that the minimal match criteria are not beneficial over one 
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Discussion 
It is known that transplantation to sensitized patients through regular allocation is associated with an 
elevated risk for graft rejection (14-16). The current study confirms these data, with the cumulative 
rejection incidence for highly sensitized patients transplanted through ETKAS being almost double 
that of non-sensitized ETKAS patients. In contrast, patients transplanted through the AM program 
showed significantly lower rejection rates compared to highly sensitized patients transplanted through 
regular allocation, and even had similar rejection rates as non-sensitized patients. Upon multivariate 
analysis, receiving a transplant through the AM program remained independently associated with low 
rejection rates in highly sensitized patients. The occurrence of rejection is known to be a risk factor 
for subsequent inferior long-term graft survival (17). Indeed, it has been described previously that 
graft survival in AM patients is far superior to that in highly sensitized patients transplanted through 
ETKAS and comparable to that in non-sensitized ETKAS patients (7). Limitations of the study are 
that it does not include information on whether the rejections were biopsy proven. In the PROCARE 
database rejection was defined as a registered treatment for rejection, of which 56.4% (n= 456) were 
accompanied by a documented biopsy taken a day prior, or at the day of initiation of anti-rejection 
treatment, a percentage that was evenly distributed between the different groups (P=0.122, 
supplemental Table 1). This is likely an underestimation due to incompleteness of the database for 
this field. To get a more stringent selection on the rejection events, we determine the 6-month 
cumulative rejection of highly sensitized patients (ETKAS and AM) without any rejection or who 
received a documented biopsy-informed anti-rejection treatment defined as described above, and 
again found that patients transplanted through AM had a significantly lower rejection incidence than 
their highly sensitized counterparts transplanted through ETKAS (supplemental Figure S2).  
Secondly, we were unable to further differentiate in type of rejection, since a classification of 
rejection is not available from the Dutch Organ Transplant Registry, and cannot be obtained 
retrospectively due to the various changes in BANFF criteria over time. Finally, there are no data 
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current study showing a marked benefit for AM patients, these parameters should be included in a 
consecutive study on a more recent cohort. 
 
The finding that allocation based on acceptable antigens results in low rejection rates and excellent 
long-term graft survival can be explained in several ways. Firstly, the absence of particular HLA 
antibody specificities is actively determined for AM patients in both historic and current sera, in 
contrast to regular allocation in which unacceptable antigens are determined, and all other antigens are 
presumed acceptable. Secondly, there is evidence that acquired neonatal tolerance explains a 
proportion of acceptable antigens, since acceptable antigens often include the noninherited maternal 
antigens (NIMA) (18, 19). Thirdly, acceptable antigens could either harbor a low level of epitope 
mismatches with the patient, or the epitope mismatches that are present are of low immunogenicity 
(20). Preliminary data suggest the latter, since analysis for HLA class I shows similar levels of epitope 
mismatches for AM patients and patients transplanted through regular allocation, with no effect of the 
number of epitope mismatches on graft survival for AM patients (Heidt et al, manuscript in 
preparation). 
Currently, acceptable antigens for HLA-DQA, HLA-DPA and HLA-DPB are not yet accounted for in 
the AM program, which leaves the possibility that rejection rates for AM patients could be even lower 
when these loci are also taken into consideration. Indeed, HLA-DQ seems to be the dominant target 
for HLA antibodies after transplantation (21, 22). Future analyses should show whether extension of 
acceptable mismatches to these additional loci will indeed lead to better outcome. Such analyses 
should preferentially be performed in the whole AM population, since in the current study only 
transplants performed in the Netherlands were included. However, the definition of acceptable 
antigens is done centrally at the Eurotransplant Reference Laboratory, using the same criteria for all 
patients within Eurotransplant. While confirmation of our results within the whole of Eurotransplant 
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Besides a previously described lack of effect of minimal match criteria on long-term graft survival in 
AM patients (3), we here show a lack of effect on rejection incidence as well, confirming that 
acceptable mismatches are truly acceptable. Together, these data strongly support downscaling the 
minimal match criteria for AM patients to one HLA-DR broad antigen match, which can result in 
around 200 additional transplants to highly sensitized patients through the AM program each year (3). 
Timely transplantation of highly sensitized patients is of the utmost importance, but should be 
accompanied by low rejection rates and long-term graft survival to have a true impact on the waiting 
list of highly sensitized patients. We here show that transplantation of highly sensitized patients can 
be achieved with comparable rejection rates to non-sensitized patients, when acceptable mismatches 
are used in the allocation process. 
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Figure legends 
Figure 1. (A) Comparison of 6-month cumulative rejection incidence between patients transplanted 
through the acceptable mismatch (AM) program or through the Eurotransplant Kidney Allocation 
System (ETKAS). (B) Comparison of 5-year cumulative rejection incidence between patients 
transplanted through the AM program or through ETKAS, for which rejection incidence was set at 
zero on 6 months. The ETKAS patients are subdivided based on their sensitization grade: 0%–5% 
peak panel reactive antibody (PRA): non-sensitized; 6%–85% peak PRA: intermediately sensitized; 
and >85% peak PRA: highly sensitized. P value calculated with log-rank test and corrected for 
multiple comparisons (Bonferroni method). 
 
Figure 2. Minimal match criteria do not affect rejection rates for patients transplanted through the 
Acceptable Mismatch (AM) program. (A) The 6-month cumulative rejection incidence of highly 
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a minimal match level of one HLA-B and one HLA-DR antigen, or two HLA-DR antigens on the split 
antigen level (equivalent to minimal match criteria), or transplanted with one HLA-DR match at the 
broad antigen level. (B) The 6-month cumulative rejection incidence of Acceptable Mismatch (AM) 
patients transplanted according to the minimal match criteria of one HLA-B and one HLA-DR 
antigen, or two HLA-DR antigens on the split antigen level, or transplanted one HLA-DR match at 
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   ETKAS     
Parameters Categories 0-5% PRA 6-85% PRA >85% PRA AM Total P 
N=1991 N=968 N=121 N=113 N=3193 
Sex of recipient Female 34,3% 48,5% 59,5% 68,1% 1301 <0.001 
Male 65,7% 51,5% 40,5% 31,9% 1892 
Sex of donor Female 48,8% 44,6% 47,9% 43,4% 1510 0.156 
Male 51,2% 55,4% 52,1% 56,6% 1683 
Age of recipient (yr) ≤50 46,3% 53,9% 64,5% 64,6% 1594 <0.001 
>50 53,7% 46,1% 35,5% 35,4% 1599 
Age of donor (yr) ≤50 57,3% 63,1% 61,2% 58,4% 1891 0.023 
>50 42,7% 36,9% 38,8% 41,6% 1302 
Donor type HB 66,5% 73,9% 90,1% 99,1% 2260 <0.001 
NHB 33,5% 26,1% 9,9% 0,9% 933 
Repeat transplant No 93,4% 71,6% 40,5% 46,0% 2654 <0.001 
Yes 6,6% 28,4% 59,5% 54,0% 539 
HLA-A, -B, -DR mismatch                        
(broad antigen level) 
1, 2, 3 82,5% 81,7% 84,3% 90,3% 2637 0.144 
4, 5, 6 17,5% 18,3% 15,7% 9,7% 556 
Transplant period 1996-2000 45,0% 57,5% 63,6% 42,5% 1577 <0.001 
2001-2005 55,0% 42,5% 36,4% 57,5% 1616 
Initial immunosuppression
*
 Pred / cyclo ± MMF ± IL2RA 65,8% 63,2% 64,7% 42,6% 1497 0.002 
Pred / tacro / MMF ± IL2RA 34,2% 36,8% 35,3% 57,4% 828 
Initial graft function
†
 Direct 64,5% 69,3% 67,3% 79,6% 1991 0.002 
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AM: acceptable mismatch, cyclo: cyclosporin, HB: heart beating, IL2RA: IL-2 receptor antagonist, MMF: mycophenolate mofetil, NHB: non-heart beating, 




  Cox regression 
Univariate Multivariate Multivariate 
HR 95% CI P HR 95% CI P HR 95% CI P 
Sex of recipient Female (ref)             
Male 0.797 0.489 1.300 0.364         
Sex of donor Female (ref)             
Male 0.949 0.599 1.504 0.824         
Age of recipient (yr) ≤50 (ref)             
>50 0.819 0.502 1.334 0.422         
Age of donor (yr) ≤50 (ref)             
>50 1.240 0.781 1.969 0.362         
Donor type HB (ref)             
NHB 1.176 0.429 4.224 0.752         
Repeat transplant No (ref)             
Yes 0.786 0.497 1.245 0.305         
HLA-A, -B, -DR mismatch  
(broad antigen level) 
1, 2, 3 (ref)             
4, 5, 6 1.353 0.712 2.570 0.356         
Luminex defined DSA No (ref)             
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Table 2. Factors affecting 6-monts cumulative rejection incidence of highly sensitized transplant recipients (>85% PRA) within PROCARE cohort (> 0 HLA-
A, -B, -DR mismatch) 
 
AM: acceptable mismatch, CI: confidence interval, cyclo: cyclosporin, DSA: donor specific antibody, HB: heart beating, HR: hazard ratio, IL2RA: IL-2 






 HLA class II 0.691 0.240 1.991 0.493         
 HLA class I and class II 1.420 0.612 3.296 0.415         
Transplant period 1996-2000 (ref)             
2001-2005 0.632 0.394 1.012 0.056     0.642 0.387 1.064 0.086 
Initial immunosuppression Pred / cyclo ± MMF ± IL2RA (ref)             
Pred / tacro / MMF ± IL2RA 0.581 0.306 1.104 0.097 0.665 0.345 1.282 0.223     
Initial graft function Direct (ref)             
Delayed 1.941 1.190 3.167 0.008     1.925 1.163 3.187 0.011 
Tx through AM program No (ref)             
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